Jefferson Health

Physician Profile

Edith Mitchell, MD, FACP

Jefferson University Physician

Academic Title: Clinical Professor
Director, Center to Eliminate Cancer Disparities
Program Leader, Gastrointestinal Oncology

Specialties
Medical Oncology - Colorectal Cancer (Not Accepting New Patients)
Medical Oncology - Esophageal Cancer
Medical Oncology - Gastrointestinal (GI) Cancer (Not Accepting New Patients)
Medical Oncology - Liver Cancer (Not Accepting New Patients)
Medical Oncology - Pancreatic Cancer (Not Accepting New Patients)
Medical Oncology - Stomach Cancer
Medical Oncology (Not Accepting New Patients)

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697

Medical Services

Years in Practice

38

Board Certifications

  • Medical Oncology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Education

  • Medical College of Virginia, Medical School

Internship

  • Meharry Medical College

Residency

  • Meharry Medical College

Fellowship

  • Georgetown University Hospital, DC

Recent Publications

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

Moonshot Toward a Cure for Cancer

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

Determinants of pain severity changes in ambulatory patients with cancer: An analysis from eastern cooperative oncology group trial E2Z02

Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA

Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass

Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer

Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept

A Randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)

Mucinous colloid carcinoma of the colon metastatic to the breast

Radiation therapy oncology group 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer

Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

Gastric cancer

Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy?

The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma

The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: The secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status

Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer

Reply to M. Rother